SAN ANTONIO--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 31st Annual San Antonio Breast Cancer Symposium on December 10-14, 2008. Data will be presented from a study highlighting the potential use of ABRAXANE (nab™-paclitaxel) in combination with other chemotherapy agents in the neoadjuvant treatment setting. The company also will present pre-clinical data evaluating the potential antitumor activity of nab-paclitaxel given in combination with two investigational therapies that utilize the company’s proprietary nanoparticle technology, nab-rapamycin and nab-IDN5404.
